NED-170

**NED-170** is an investigational oral fixed-dose, seven-component anticancer combination developed by NED Biosystems for advanced solid tumors. It combines alpha-lipoic acid, curcumin, cyclophosphamide, genistein, melatonin, metformin, and naltrexone in a low-dose systems-treatment regimen intended to concurrently modulate cancer-driving processes including angiogenesis, impaired apoptosis, altered tumor metabolism, and immune evasion. The program has been described for cholangiocarcinoma, ovarian cancer, and triple-negative breast cancer, including use alongside standard care in patients without an actionable tumor-genomic target. ([nedbiosystems.com](https://nedbiosystems.com/press/ned-biosystems-gains-patent-for-unique-combination-therapy/))